Trials / Completed
CompletedNCT00499200
Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy
A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Accepted
Summary
The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease (AD) subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SRA-444 |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-07-11
- Last updated
- 2008-07-09
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00499200. Inclusion in this directory is not an endorsement.